Neuroprotection for ischaemic stroke - An unattainable goal?

Neuroprotective therapies for acute ischaemic stroke have yet to be realise d despite the determined efforts of basic science and clinical investigator s. Progressive elucidation of the complex pathophysiology involved in the i schaemic cascade has led to the development of numerous candidate intervent ions. Preliminary efficacy in animal models has repeatedly resulted in frus tration after extensive clinical testing. Failure in the translation of res ults from animal models to humans implicates potential limitations of the c urrent drug development process. Reflection on prior studies suggests possi ble flaws at several stages. Incorporation of standardised guidelines for p reclinical testing of putative neuroprotective therapies and modification o f clinical trial design. methodology and reporting may improve chances for success. The future of neuroprotection for stroke remains bright in spite o f previous disappointments.